KIM, YOUNG KWAN,김영관,KIM, MYOUNG YEOL,김명열,JOO, HYUN WOO,주현우,PARK, HEUI SUL,박희술,SHIM, DONG SUP,심동섭,KWAK, HYO SHIN,곽효신,LEE, TAE HEE,이태희,CHOI, EUN SIL,최은실
申请号：
KR1020120015736
公开号：
KR1020120094859A
申请日:
2012.02.16
申请国别(地区):
KR
年份:
2012
代理人:
摘要：
PURPOSE: An oxime derivative as a GPR119 effector, a manufacturing method thereof, a pharmaceutical composition including the same are provided to act as a GPR119 effector which increases insulin secretion and promotes GLP-1 secretion. CONSTITUTION: An oxime derivative as a GPR119 effector is represented by chemical formula 1. The GPR119 effector includes an oxime derivative represented by the chemical formula 1, a pharmaceutically allowed carrier, pharmaceutically allowed salt or isomer as an active component. A pharmaceutical composition for preventing or treating diabetes, complication of the diabetes, obesity, and dyslipidemia contains the oxime derivative represented by the chemical formula 1, pharmaceutically allowed salt or the isomer and the pharmaceutically allowed carrier as an active component. The diabetes is type 2 diabetes. A composition for decreasing the blood glucose contains the oxime derivative represented by the chemical formula 1, pharmaceutically allowed salt or the isomer and the pharmaceutically allowed carrier as an active component. A manufacturing method of composition for preventing or treating diabetes complication of the diabetes, obesity, dyslipidemia or osteoporosis comprises the following step: mixing the pharmaceutically allowed carrier with the pharmaceutically allowed compound represented by the chemical formula 1, the pharmaceutically allowed salt or isomer.본 발명은 하기 화학식 1의 옥심 유도체, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 사용 방법에 관한 것이다. 특히, 본 발명에 따른 옥심 유도체는 제2형 당뇨병, 당뇨병의 합병증, 비만, 이상지질혈증(dyslipidemia) 또는 골다공증 치료를 위해 GLP-1의 분비를 촉진시키고 또한 인슐린 분비를 증가시키는 GPR119 효능제로서 작용할 수 있다. [화학식 1]상기 식에서 RA, RB, n, Ar, A, B, R1 및 R2 는 명세서 중에 정의된 바와 같다.
